Hudson Robotics announces its new fully automated colony isolation workcell combining picking, incubation, media dispensing and library management

Abbott receives FDA approval for a new six-month formulation of Lupron Depot®
Abbott has announced that the FDA has approved a new 45 mg for six-month administration formulation of Lupron Depot® (leuprolide acetate for depot suspension), a medication used for the palliative treatment of advanced prostate cancer...

Boehringer Ingelheim extends "one stop shop" service
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line...

Pivotal study showed vismodegib helped shrink skin cancer tumours
Pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate...

Pfizer and Acura announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII
Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. FDA of OXECTATM (oxycodone HCl, USP) Tablets CII...

New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA®
New data show that TWYNSTA®, a once daily, single pill combination of the angiotensin II receptor blocker (ARB) telmisartan and the calcium channel blocker (CCB) amlodipine, leads to prompt and very effective reductions in blood pressure in hypertensive patients with diabetes...

Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant
Novartis held a groundbreaking ceremony to announce the start of construction of a pharmaceutical manufacturing plant in St. Petersburg, Russia. The construction of this facility represents the most significant Novartis investment in Russia to date...

Sanofi enters into research collaboration with Audion Therapeutics
Sanofi has announced that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach...

Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA
Novartis has announced that the FDA has accepted for review its supplemental Biologics License Application (sBLA) to expand the Menveo® (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) indication to include infants and toddlers from 2 months of age...

Reata and Abbott initiate global Phase 3 study of bardoxolone methyl in patients with chronic kidney Disease and type 2 diabetes
Reata and Abbott have announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes...

AstraZeneca extends its investment in Russia with new predictive science centre in St Petersburg
AstraZeneca has announced that it plans to establish a Predictive Science Centre in St. Petersburg over the coming year. The move strengthens AstraZeneca’s investments in Russia and supports the Russian Government’s strategy to modernise and develop the country’s pharmaceutical sector...

Horizon successfully completes pilot human gene-editing program
Horizon Discovery has announced that it has successfully completed an eighteen month pilot program with Novartis, designed to test the ability of Horizon’s GENESISTM rAAV gene-editing platform to generate human isogenic cell lines for use by Novartis pre-clinical research programs...